Efficacy of Long-term Sublingual Immunotherapy as an Adjunct to Pharmacotherapy in House Dust Mite-Allergic Children With Asthma
Authors: Skripak Justin M. , Wood Robert A. 
Published: October 2008

Ozdemir C, Yazi D, Gocmen I, et al. Pediatr Allergy Immunol. 2007;18(6):508–515
PURPOSE OF THE STUDY. To evaluate the effect of 3 years of dust mite sublingual immunotherapy (SLIT) on clinical and laboratory outcome measurements.
STUDY POPULATION. This was a prospective study of 90 children aged 4 to 16 years who were followed for 4 years from the time of enrollment. Inclusion criteria were mild-to-moderate persistent asthma requiring an inhaled steroid, monosensitization to dust mite, and no previous history of immunotherapy.
METHODS. Participants were randomly assigned to treatment for 3 years with dust mite SLIT plus standard pharmacotherapy or pharmacotherapy alone. The prescribed SLIT solution consisted of 50% Dermatophagoides pteronyssinus and 50% Dermatophagoides farinae. Doses were increased gradually to a maintenance dose, which was taken 2 times per week. All participants were initially started on 800 μg/day of inhaled budesonide. Follow-up visits were performed every 2 to 3 months, at which times the inhaled corticosteroid (ICS) dose was decreased until either it was discontinued or the minimum dose allowing for control of symptoms was reached. Pulmonary-function testing was performed at each visit. Skin-prick testing to 15 aeroallergens and a serum total immunoglobulin E measurement were performed annually.
RESULTS. A total of 90 children were randomly assigned: 62 to SLIT plus pharmacotherapy and 28 to pharmacotherapy alone. There were 19 drop-outs (31%) in the SLIT group after 3 years compared with 5 (18%) in the pharmacotherapy group. The number of months per year in which the children required ICS, as well as mean dose per day of budesonide, was significantly lower in the SLIT group compared with pharmacotherapy group during all 3 years. By the end of the 3 years, 52.4% in the SLIT group versus 9.1% in the pharmacotherapy group were able to successfully discontinue ICSs for at least 6 months. Both forced expiratory volume in 1 second and forced expiratory flow, midexpiratory phase, were significantly increased from baseline in the SLIT group after 3 years, whereas the pharmacotherapy controls showed no change. Total immunoglobulin E levels were significantly decreased only in the SLIT group after 3 years. Finally, there were no serious adverse reactions during the study.
CONCLUSIONS. Three years of SLIT as an adjunct to pharmacotherapy in house dust mite–allergic children with asthma resulted in a reduction of the necessity for ICS usage along with improvement in lung functions.
REVIEWER COMMENTS. This study adds to the body of work defining SLIT as a modality that is capable of providing clear but modest benefit in the treatment of allergic airway disease. The primary focus was on evaluating the steroid-sparing effect of SLIT. Unfortunately, symptom scores and rescue-medication usage were not reported. There was a 31% drop-out rate after 3 years among the SLIT group, compared with 18% among the pharmacotherapy group. So, although there may be some compliance advantage in SLIT over injection immunotherapy, there are clearly still some adherence challenges. This study demonstrates that the addition of SLIT to standard pharmacotherapy can provide a significant decreases in ICS usage and modest increases in lung function over the course of 3 years of treatment.